StockMarketWire.com - Motif Bio said it had signed an agreement with Otto-von-Guericke University Magdeburg to conduct a study evaluating iclaprim in an in-vitro model of ocular toxoplasmosis.

The research would focus on toxoplasma chorioretinitis, an orphan disease that is a type of ocular toxoplasmosis, a parasitic disease that may result in severe life-threatening infections and blindness.

The work would be led by Prof. Dr. Ildiko Rita Dunay, Director, Institute of Inflammation and Neurodegeneration at the university.

'We are very pleased to work with Dr. Dunay, who is an expert in the area of toxoplasmosis,' chief medical officer David Huang said.

'In vitro data indicate that iclaprim has activity against toxoplasma.'

'The data generated from Dr. Dunay's lab will be important in understanding whether iclaprim can play a role in this potentially devastating, progressive and recurring necrotizing retinitis, including vision-threatening complications.'


At 9:39am: [LON:MTFB] Motif Bio Plc Ord 1p share price was +0.35p at 7.75p



Story provided by StockMarketWire.com